Your browser doesn't support javascript.
loading
Neuromelanin levels in individuals with substance use disorders: A systematic review and meta-analysis.
Ahrens, Jessica; Zaher, Farida; Rabin, Rachel A; Cassidy, Clifford M; Palaniyappan, Lena.
Afiliación
  • Ahrens J; Douglas Research Centre, Douglas Mental Health Research Institute, Montreal, Quebec, Canada; Integrated Program in Neuroscience, McGill University, Montreal, Quebec, Canada.
  • Zaher F; Douglas Research Centre, Douglas Mental Health Research Institute, Montreal, Quebec, Canada; Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
  • Rabin RA; Douglas Research Centre, Douglas Mental Health Research Institute, Montreal, Quebec, Canada; Integrated Program in Neuroscience, McGill University, Montreal, Quebec, Canada; Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
  • Cassidy CM; Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA.
  • Palaniyappan L; Douglas Research Centre, Douglas Mental Health Research Institute, Montreal, Quebec, Canada; Integrated Program in Neuroscience, McGill University, Montreal, Quebec, Canada; Department of Psychiatry, McGill University, Montreal, Quebec, Canada; Robarts Research Institute, University of Western Ontar
Neurosci Biobehav Rev ; 161: 105690, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38678736
ABSTRACT
Dopamine's role in addiction has been extensively studied, revealing disruptions in its functioning throughout all addiction stages. Neuromelanin in the substantia nigra (SN) may reflect dopamine auto-oxidation, and can be quantified using neuromelaninsensitive magnetic resonance imaging (neuromelanin-MRI) in a non-invasive manner.In this pre-registered systematic review, we assess the current body of evidence related to neuromelanin levels in substance use disorders, using both post-mortem and MRI examinations. The systematic search identified 10 relevant articles, primarily focusing on the substantia nigra. An early-stage meta-analysis (n = 6) revealed varied observations ranging from standardized mean differences of -3.55 to +0.62, with a pooled estimate of -0.44 (95 % CI = -1.52, 0.65), but there was insufficient power to detect differences in neuromelanin content among individuals with substance use disorders. Our gap analysis highlights the lack of sufficient replication studies, with existing studies lacking the power to detect a true difference, and a complete lack of neuromelanin studies on certain substances of clinical interest. We provide recommendations for future studies of dopaminergic neurobiology in addictions and related psychiatric comorbidities.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Trastornos Relacionados con Sustancias / Melaninas Límite: Humans Idioma: En Revista: Neurosci Biobehav Rev Año: 2024 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Trastornos Relacionados con Sustancias / Melaninas Límite: Humans Idioma: En Revista: Neurosci Biobehav Rev Año: 2024 Tipo del documento: Article